<DOC>
	<DOCNO>NCT00575757</DOCNO>
	<brief_summary>Because NASH recognize significant cause cirrhosis associate morbidity mortality , recognition long term complication HAART important management living HIV .</brief_summary>
	<brief_title>Relationship Metabolic Abnormalities Hepatic Steatosis HIV</brief_title>
	<detailed_description>Abnormal liver enzymes frequently see HIV . Although many individual co-infected HBV HCV , histology HIV patient abnormal liver enzyme absence viral hepatitis explore . HAART significantly improve survival living HIV . However , component HAART , particularly protease inhibitor ( PIs ) certain nucleoside reverse transcriptase inhibitor ( NRTIs ) , frequently associate metabolic abnormality include insulin resistance ( IR ) , dyslipidemias , fat redistribution lipodystrophy ( LD ) . Both IR dyslipidemia pathogenic mechanism associate nonalcoholic fatty liver disease ( NAFLD ) non-alcoholic steatohepatitis ( NASH ) often present asymptomatic liver enzyme elevation . Because NASH recognize significant cause cirrhosis associate morbidity mortality , recognition long term complication HAART important management living HIV . In HIV population without HCV HBV , high prevalence abnormal liver enzyme ( AST 21 % , ALT 16 % , ALP 43 % ) compare general population ( ALT 8 % ) independently associate PI use . The relationship liver enzyme abnormality IR , dyslipidemias , development hepatic steatosis/NASH HIV patient unknown . We hypothesize Liver enzyme abnormality HIV positive patient without viral hepatitis co-infections HAART due hepatic steatosis relate PI use subset individual NASH . The Specific Aims focus HIV positive patient abnormal liver enzyme absence viral hepatitis co-infections , diabetes , alcohol abuse answer follow three question : ( 1 ) What spectrum NAFLD ? ; ( 2 ) How spectrum compare PI compare ; ( 3 ) What independent predictive factor associate hepatic steatosis NASH ? These study ( 1 ) provide novel data histology HIV infect patient abnormal liver enzyme absence viral coinfections relationship IR , LD , dyslipidemias , HAART use ( 2 ) provide necessary pilot data multicenter R0-1 grant study long-term impact HAART development steatohepatitis subsequent hepatic fibrosis .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<criteria>HIV antibody positive . Age &gt; 18 year Abnormal liver chemistry ( AST , ALT , and/or ALP ) define 1.25 5 x ULN . Hepatic decompensation : coagulopathy ( prothrombin time prolong &gt; 2 second , INR &gt; 1.5 ) , ascites , hepatic encephalopathy , jaundice ( serum conjugate bilirubin &gt; 3.0 ) Thrombocytopenia ( platelet &lt; 80,000 ) Use vitamin E , thiazolidinediones , metformin Use medication associate steatosis : amiodarone , methotrexate , corticosteroid , estrogen , tamoxifen Renal failure ( serum creatinine &gt; 3.0 ) Diabetes mellitus Advanced HIV disease life expectancy le 1 year Alcohol use ( &gt; 40 grams/day men 20 grams/day woman ) Presence HCV RNA HBV surface antigen Other liver disease include alpha1 antitrypsin ( A1AT ) deficiency , autoimmune hepatitis , hemochromatosis , Wilson 's disease , HIV cholangiopathy , bacillary angiomatosis , lymphoma , Kaposi 's sarcoma Inability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Steatosis</keyword>
	<keyword>NASH</keyword>
</DOC>